Introduction {#Sec1}
============

The human genome encodes for approximately 80 putative deubiquitinating enzymes (DUBs), including cysteine proteases and several metalloproteases \[[@CR1]\]. The diverse functions that DUBs play within the cell can be classified into three major categories. Firstly, DUBs process linear polyubiquitin precursor proteins, such as ribosomal fusion proteins, into single ubiquitin molecules (reviewed in \[[@CR2]\]). Secondly, DUBs recycle ubiquitin by processing polyubiquitin chains to generate free ubiquitin that can subsequently enter the ubiquitin pool for subsequent ubiquitin conjugation events. This is a critical process since free polyubiquitin chains can inhibit the binding of polyubiquitinated substrates to the 26S proteasome competitively \[[@CR3]--[@CR5]\]. Finally, DUBs remove ubiquitin from ubiquitinated substrates, antagonizing ubiquitin conjugation by E3 ligases \[[@CR6], [@CR7]\]. The vast number of DUBs belonging to five distinct protein families suggests that there is a specialization in terms of their function and specificity. Indeed, it has been demonstrated that DUBs target distinct pathways and their localization may be limited to certain subcellular compartments \[[@CR1], [@CR8]\]. Moreover, many DUBs have been linked to pathological conditions, underlying their physiological significance in health and disease (reviewed in \[[@CR9]\]).

Modes of Regulation of DUB Activity {#Sec2}
===================================

Since the catalytic activity of DUBs is so specific and in many cases functionally critical, one would anticipate multiple mechanisms of its control, and several ones have been already described (reviewed in \[[@CR10]\]). DUBs are generally expressed as active enzymes, rather than inactive precursors. However, certain DUBs require ubiquitin binding to obtain their active conformation and that prevents their uncontrolled proteolytic activity. The structural data for several DUBs reveal that ubiquitin-binding by DUBs is accompanied by active site rearrangements and that such conformational alterations induce their hydrolytic activity, which has been demonstrated for OTUB1, UCH-L1, UCH-L3, USP7, USP14, and *S. cerevisiae* YUH1 \[[@CR11]--[@CR19]\]. Another way of modulating DUB activity is through the binding of scaffold and adaptor proteins. Some DUBs display low affinity for ubiquitin and therefore require additional interactors for binding ubiquitinated substrates efficiently \[[@CR20]\]. DUBs may require to be incorporated into large macromolecular complexes to attain the active state, exemplified by USP14 or POH1 that are activated by their binding to the 26S proteasome complex \[[@CR10], [@CR21], [@CR22]\]. Activation of USP8 and AMSH is facilitated by signal transducing adaptor molecule 2 (STAM2), and both proteins are involved in regulating endocytic trafficking \[[@CR23]\]. Protein--protein interactions can also inhibit protease activity, for example UCH37 function is inhibited by its binding to the chromatin-remodeling complex \[[@CR24]\]. Proteolytic cleavage of DUBs is another way of regulation of their function. This is exemplified by USP1, which undergoes autoproteolysis that in turn inactivates this enzyme \[[@CR25]\]. Last but not least, many DUBs are subjected to post-translational modifications (PTMs), possibly representing an effective and reversible means of regulating their activity or function. This review will discuss the documented examples of the PTMs in DUBs and their various phenotypic consequences (summarized in Table [1](#Tab1){ref-type="table"}).Table 1Review of characterized post-translational modifications (PTMs) of deubiquitinating enzymes (DUBs)DUBModificationResidueDomainModifying enzymePhysiological effectReferencesA20PhosphorylationSer381Catalytic regionI kappa B kinase betaIncreased A20-mediated downregulation of NF-κB\[[@CR41]\]Ataxin-3UbiquitinationEnhancement of catalytic activity\[[@CR45]\]Ataxin-3PhosphorylationSer340, Ser352UIMCK2Influence on nuclear localization, aggregation, and stability\[[@CR46]\]CYLDPhosphorylationMultiple residues within region 447--956, including Ser418Within close proximity to the TRAF2-binding sitePossibly IkB kinase gamma, alpha or epsilonSuppression of TRAF2 deubiquitination\[[@CR34], [@CR35]\]OTUB1PhosphorylationSer16, Ser18, Tyr26*N*-terminus with unknown functionSuppression of catalytic activity and protein--protein interaction\[[@CR50]\]Ubp-M (USP16)PhosphorylationPhosphorylated form is enzymatically active; phosphorylation is associated with the mitosis and dephosphorylation with the metaphase/anaphase transition\[[@CR53], [@CR54]\]UCH-L1*O*-glycosylation*O*-glycosylated in the nerve terminals\[[@CR56]\]UCH-L1MonoubiquitinationMultiple, including Lys4, Lys65, Lys71, Lys157Within close proximity to the active siteSuppression of catalytic activity by preventing binding to ubiquitinated targets\[[@CR57]\]USP10PhosphorylationThr42 and Ser337Thr42 is within the protein--protein interaction domainATMAffected translocation and stabilization\[[@CR76]\]USP25MonoubiquitinationLys99UIMHypothesized activation of catalytic activity\[[@CR78]\]USP25PhosphorylationTyr740SYKNegative effect on protein stabilization\[[@CR80]\]USP25SumoylationLys99, Lys141UIMInhibition of catalytic activity\[[@CR81]\]USP4UbiquitinationRo52 (TRIM21)Unknown; possibly part of the transregulation mechanism toward Ro52\[[@CR121]\]USP44PhosphorylationPhosphorylation during mitosis\[[@CR85]\]USP44Lys48- and Lys63-polyubiquitination\[[@CR84]\]USP6Mono-/poly-ubiquitinationMonoubiquitination depends on its association with calcium (Ca^2+^)-binding protein calmodulin (CaM)\[[@CR59]\]USP7PhosphorylationSer18 and Ser963Within close proximity to protein--protein interaction domains\[[@CR65], [@CR66]\]USP7UbiquitinationLys869Within close proximity to protein--protein interaction domains\[[@CR66]\]USP8PhosphorylationSer680Suppression of catalytic activity, alteration of the subcellular localization\[[@CR69]\]USP8PhosphorylationTyrosine phosphorylation*N*-terminus\[[@CR73]\]USP8PhosphorylationThr907Akt-mediatedPossibly increased protein stability\[[@CR74], [@CR75]\]USP28PhosphorylationSer67, Ser714Possibly ATMPhosphorylated in response to ionizing irradiation\[[@CR83]\]Information includes the type of a PTM, modified residues, affected domains within a DUB, the modifying enzyme(s) and a physiological effect of the PTM

Phosphorylation of CYLD in the NF-κB Pathway {#Sec3}
============================================

The ubiquitin-specific protease involved in cylindromatosis (CYLD) is one of the best studied examples of post-translationally modified DUBs. CYLD specifically cleaves Lys^63^-linked polyubiquitin chains and acts on TRAF2, TRAF6, and several other substrates, which results in negative regulation of the NF-κB pathway (\[[@CR26]--[@CR28]\], reviewed in \[[@CR29]\]). CYLD is a tumor suppressor and an important player in the host defense mechanisms against bacterial infection, as shown for several pathogens \[[@CR30]--[@CR33]\]. CYLD becomes phosphorylated as a response to treatment with a number of NF-κB-inducing factors, such as LPS or TNF-α \[[@CR34]\]. This transient modification occurs at several sites in a region located within close proximity to the TRAF2-binding site, which includes Ser^418^. The biochemical analysis using phosphomimetic mutants demonstrated that this PTM negatively affects the deubiquitinating activity of CYLD on TRAF2, most likely through interfering with the catalytic activity of CYLD, since the binding of TRAF2 to a CYLD mutant mimicking phosphorylation on Ser^418^ is not affected (Fig. [1](#Fig1){ref-type="fig"}a; \[[@CR34]\]). There is some initial evidence that IKKγ (I kappa B kinase gamma) mediates CYLD phosphorylation on Ser^418^ \[[@CR34]\], although a more recent report suggests that IKKε (I kappa B kinase epsilon) is a much more efficient kinase for this site \[[@CR35]\]. Interestingly, IKKα (I kappa B kinase alpha) and IKKß (I kappa B kinase beta) are also able to phosphorylate CYLD in vitro, although in vivo they require additional assistance of IKKγ. In addition to down-regulation of the NF-κB pathway \[[@CR34]\], CYLD phosphorylation has been demonstrated to have a physiological relevance in increasing cell transformation \[[@CR35]\], hence precise identification of a kinase or a kinase cascade involved in this process might provide potential targets for pharmacological intervention strategies in the treatment of cancer.Fig. 1PTMs in control of DUB activity exemplified by CYLD and UCH-L1. **a** Phosphorylation of CYLD impairs its deubiquitinating activity toward TRAF2. CYLD cleaves Lys^63^-linked polyubiquitin chains from TRAF2, which results in negative regulation of the NF-κB pathway by inactivation of kinases JNK and IKK. IKKγ-mediated phosphorylation impairs its catalytic activity, in effect contributing to activation of JNK and IKK and positive regulation of NF-κB. **b** Monoubiquitination of UCH-L1 modulates its enzymatic function. UCH-L1 shortens conjugated polyubiquitin chains on the substrate proteins, and monoubiquitination of UCH-L1 hinders this activity by impairing its binding to ubiquitin. UCH-L1 is able to self-regulate its own ubiquitination status through auto-deubiquitination

Phosphorylation-Regulated Activity of A20 {#Sec4}
=========================================

A20 is an ovarian tumor domain (OTU)-containing protease with a well-defined function in pro-inflammatory events. It down-regulates activation of the transcription factor NF-κB and therefore plays an important role in inflammation \[[@CR36]--[@CR38]\]. Interestingly, next to the OTU domain involved in cleavage of Lys^63^-linked polyubiquitin chains from the protein substrates TRAFs, RIPs and NEMO, it also contains the *C*-terminal zinc finger domain that acts as a ubiquitin ligase and is responsible for building Lys^48^-linked polyubiquitin conjugates on RIPs, thus targeting them to the proteasome \[[@CR39], [@CR40]\]. Therefore, A20 has a dual, or editing function on its substrates, removing one type of polyubiquitin chain and attaching another. A positional scanning peptide library technique combined with a bioinformatics approach identified A20 as a putative substrate for the IKKß kinase. Mass spectrometric analysis mapped the phosphorylation site to Ser^381^ that was verified in vitro and in vivo. IKKß-mediated A20 phosphorylation has been shown to increase its activity toward NEMO, thereby further down-regulating the NF-κB pathway. It is not conclusive, however, whether phosphorylation on Ser^381^ affects the E3 ubiquitin ligase or deubiquitinase activity of A20, although the modification occurs at the zinc finger domain of the protein, so the former would be expected \[[@CR41]\].

Post-Translational Modifications Modulate Function of Ataxin-3 {#Sec5}
==============================================================

Ataxin-3 (AT3) is a polyglutamine disease protein regulating ERAD substrate trafficking to the proteasome. It contains an *N*-terminal Josephin domain \[[@CR42]\] and preferentially cleaves Lys^63^-polyubiquitin chains, displaying even higher activity toward Lys^63^-ubiquitin linkages that are within mixed linkage ubiquitin chains \[[@CR43]\]. AT3 undergoes ubiquitination \[[@CR44]\], which increases its ability to process hexa-ubiquitin chains but in the tested conditions it does not alter its specificity to the linkage type \[[@CR45]\]. This observation has been made for both wild-type AT3 and the pathogenic AT3 with polyQ expansion causing a neurodegenerative disorder, spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD). Ubiquitination of AT3 can be induced by certain stress factors, including inhibition of the proteasome or treatment with dithiothreitol (DTT) that promotes the unfolded protein response (UPR). It has therefore been proposed that AT3 is regulated by a feedback loop mechanism that helps to restore the homeostasis related to the ubiquitin pathway \[[@CR45]\]. Moreover, AT3 is phosphorylated by protein casein kinase 2 (CK2). Phosphorylation occurs within the ubiquitin interacting motif (UIM) of AT3 and is critical for the nuclear localization of normal and pathogenic AT3. Inhibition of AT3 phosphorylation contributes to its decreased translocation to the nucleus and formation of nuclear inclusions. CK2-dependent phosphorylation of AT3 might be crucial in the stress response, because thermal stress has been shown to increase the CK2-modulated nuclear abundance of AT3. Furthermore, phosphorylation might also stabilize AT3, as observed in a pulse-chase experiment using an AT3 mutant mimicking phosphorylation \[[@CR46]\].

Otubain 1 Phosphorylation Interferes with its Catalytic Activity and Function in Bacterial Infection {#Sec6}
====================================================================================================

Otubain 1 (OTUB1), a member of OTU-containing protein family, is the only DUB for which specificity for Lys^48^-ubiquitin linkages has been clearly documented \[[@CR12], [@CR47]\]. OTUB1 functions in *T* cell anergy \[[@CR48], [@CR49]\], infection with *Yersinia* \[[@CR50]\] and in DNA double strand break repair \[[@CR51]\]. OTUB1 is predicted to have multiple phosphorylation sites, and three of them have been mapped to Ser^16^, Ser^18^, and Tyr^26^ \[[@CR50]\]. Phosphomimicry analysis suggests that phosphorylation on these sites influences protein--protein binding and the ability of OTUB1 to react with a ubiquitin-based active-site probe, indicating reduction of its catalytic activity. OTUB1-mediated stabilization of a small GTPase RhoA involved in cytoskeletal alterations has been negatively regulated by phosphorylation, which might be either due to decreased protein--protein binding capabilities or a lower catalytic activity. Finally, the physiological relevance of this modification is highlighted by the fact that OTUB1 phosphomimetic mutants did not influence bacterial invasion, in contrast to the wildtype OTUB1 \[[@CR50]\]. The phosphorylation sites are all located in the *N*-terminal part of OTUB1, a domain that has been shown to be critical to exert its function in regulating DNA double strand break repair, indicating a possible regulatory mechanism \[[@CR51], [@CR52]\].

Ubp-M Phosphorylation on the Onset of Mitosis {#Sec7}
=============================================

A novel ubiquitin-processing protease Ubp-M (USP16) has been recently identified in the pool of proteins phosphorylated during mitosis \[[@CR53]\]. Its function is yet unknown, but it has been postulated that Ubp-M might interfere with cell viability by modifying chromatin functions. The fact that Ubp-M is capable of deubiquitinating histone H2A in vitro is consistent with this hypothesis. Interestingly, phosphorylation does not interfere with the enzymatic activity of this DUB, but it does correlate with histone H2A deubiquitination during the cell cycle. Ubp-M gets rapidly dephosphorylated during a shift from metaphase to anaphase \[[@CR53], [@CR54]\].

Post-Translational Modifications of UCH-L1 Involved in Neurodegenerative Diseases {#Sec8}
=================================================================================

UCH-L1, a ubiquitin *C*-terminal hydrolase involved in Parkinson's disease and other neurodegenerative disorders (reviewed in \[[@CR55]\]), is highly expressed in neurons but its substrates and function have not yet been defined. UCH-L1 is *O*-glycosylated in the nerve terminals, although this modification has not been shown to have any effect on its function \[[@CR56]\]. Moreover, UCH-L1 undergoes monoubiquitination at multiple lysines within close proximity to its active site. This PTM appears to control the enzymatic function of UCH-L1 since monoubiquitination impairs its binding to ubiquitin and an ability to increase the monoubiquitin pool in cells, but it has no effect on its localization (Fig. [1](#Fig1){ref-type="fig"}b). Importantly, UCH-L1 is able to regulate its own ubiquitination status through auto-deubiquitination, therefore controlling its catalytic capabilities in an auto-regulatory feedback loop \[[@CR57]\].

Ubiquitination of USP6 in the Context of Protein--Protein Interaction {#Sec9}
=====================================================================

USP6 (TRE17) is a ubiquitin-specific protease implicated in human neoplasia with unidentified targets for its DUB activity \[[@CR58]\]. It has been shown to be mono- and poly-ubiquitinated, and mono-ubiquitination of USP6 depends on its association with calcium (Ca^2+^)-binding protein calmodulin (CaM). USP6 can promote its own deubiquitination, suggesting a possible mode of auto-regulation, but the physiological relevance of this modification, including the effect on its catalytic activity, remains to be uncovered \[[@CR59]\].

USP7---A Deubiquitinase Involved in Tumor Development is Phosphorylated and Ubiquitinated {#Sec10}
=========================================================================================

USP7 (Herpes-associated USP; HAUSP), a DUB described predominantly for its role in cancer biology, is involved in processes such as transcriptional regulation, DNA replication, apoptosis, and possibly in endosomal organization (\[[@CR60]\], reviewed in \[[@CR61], [@CR62]\]). It interacts with p53, Hdm2 and Hdmx, and its deubiquitinating function towards these proteins protects cells from apoptosis \[[@CR63], [@CR64]\]. PTMs documented for USP7 include phosphorylation on Ser^18^ and Ser^963^, and ubiquitination on Lys^869^, although any relation of these modifications to its activity has not been demonstrated so far \[[@CR65], [@CR66]\]. Ser^18^ is likely to be a target for casein kinase 2 (CK2)-mediated phosphorylation, especially since CK2 co-immunoprecipitates with USP7, suggesting their possible interaction \[[@CR66]\]. Both phosphorylation sites of USP7 are located near its protein--protein interaction domains, similarly to the ones of CYLD \[[@CR34]\]. It is therefore plausible that this modification might have an effect on USP7 substrates or possibly other protein interactions. Interestingly, the ubiquitination site of USP7 is placed close to the region where it was reported to interact with ICP0, a viral E3 ubiquitin ligase \[[@CR67]\], supporting the previous finding that ICP0 targets USP7 for ubiquitination \[[@CR68]\].

Role of Phosphorylation Events in the Activity and Stability of USP8 {#Sec11}
====================================================================

USP8 (UBPY) plays a role in endosomal sorting by deubiquitinating ligand-activated epidermal growth factor (EGFR) on early endosomes \[[@CR69]\]. A mass spectrometry-based analysis of the phosphoproteome identified USP8 as an interactor of 14-3-3ε during anaphase, and two independent studies mapped the phosphorylation site to Ser^680^ \[[@CR70], [@CR71]\]. This site has been then demonstrated to be critical for the subcellular localization of USP8, and while the wildtype USP8 localizes primarily to the cytosol, the majority of USP8 was found in the nucleus if the Ser^680^ was mutated to alanine \[[@CR70], [@CR71]\], but this finding was not supported by another study \[[@CR72]\]. Furthermore, the catalytic activity of USP8 is inhibited by phosphorylation on Ser^680^, based on the fact that the S680A mutant of USP8 exhibites enhanced DUB activity toward polyubiquitin chains and EGFR. This phosphorylation-mediated regulation of USP8 is present during the interphase, while during the M phase USP8 is dephosphorylated \[[@CR72]\]. Another study found USP8 to be a substrate for the EGF-activated Src-family tyrosine kinases although its biological significance is not yet understood and the phosphorylation sites mediated by these kinases have not been mapped thus far \[[@CR73]\]. USP8 is also phosphorylated by Akt on Thr^907^, which contributes to its stability \[[@CR74], [@CR75]\].

Translocation and Stabilization of USP10 is Mediated by Phosphorylation {#Sec12}
=======================================================================

USP10 has been recently described as a DUB targeting p53 for polyubiquitin chain cleavage \[[@CR76]\]. As mentioned earlier, USP7 is a DUB that deubiquitinates p53 and its E3 ligase Hdm2 \[[@CR63]\], but in contrast to USP7, USP10 has been only found to interact with and deubiquitinate p53, and it is predominantly localized in the cytoplasm in unstressed cells, while USP7 is mainly a nuclear protein \[[@CR76]\]. Therefore, while USP7 targets p53 in the nucleus, USP10 deubiquitinates cytoplasmic p53 and upon genotoxic stress it translocates to the nucleus to activate p53. ATM phosphorylates USP10 on Thr^42^ and Ser^337^, and this event is required for the stabilization of USP10 and its translocation into nucleus after DNA damage. The alanine mutation of the Thr^42^/Ser^337^ has not been shown to interfere with the capability of USP10 to deubiquitinate p53, but it impedes its nucleolar translocation and stabilization, which in effect suppresses USP10-mediated activation of p53 in response to DNA damage \[[@CR76]\].

Various PTMs of USP25 and their Effect on its Catalytic Activity {#Sec13}
================================================================

The physiological role of USP25, a member of the USP family \[[@CR77]\] remains to be explored. This USP contains a ubiquitin-associated domain (UBA) as well as two ubiquitin binding-domains (UBDs, \[[@CR78]\]), and its muscular isoform interacts with three sarcomeric proteins, having a stabilizing effect on one of them, myosin binding protein C1 (MyBPC1; \[[@CR79]\]). Recently, the tyrosine kinase SYK has been found to phosphorylate USP25, predictably on the Tyr^740^ residue. The protease activity of USP25 is not affected by SYK-mediated phosphorylation, but it decreases its protein levels, although not due to its increased proteasomal degradation \[[@CR80]\]. USP25 is also modified by SUMO-1 and SUMO-2/3, among which the latter PTM has been shown to be more predominant. Sumoylation occurs on Lys^99^ and Lys^141^, which are located within the ubiquitin-interacting motif (UIM), required for the protease activity of USP25. USP25 sumoylation indeed inhibits the catalytic activity of USP25 imposed by its reduced binding to polyubiquitin chains \[[@CR81]\]. Moreover, ubiquitination of muscular isoforms of USP25 has also been detected, and similarly to sumoylation it affected Lys^99^. Mutation of this residue negatively regulates USP25-mediated stabilization of MyBPC1 and a mutually exclusive modification on Lys^99^---sumoylation and ubiquitination---might have opposite effects on the enzyme isopeptidase activity. Importantly, USP25 is able to auto-deubiquitinate itself possibly representing a mechanism of auto-regulation \[[@CR78]\].

ATM/IR-Dependent Phosphorylation of USP28 {#Sec14}
=========================================

A deubiquitinase USP28 binds to the SCF^Fbw7^ ubiquitin E3 ligase, stabilizing Myc, and therefore promoting cell proliferation \[[@CR82]\]. Moreover, USP28 binds checkpoint proteins 53BP1, Claspin, and Mdc1 \[[@CR83]\]. In response to IR, USP28 becomes phosphorylated on Ser^67^ and Ser^714^ in an ATM-dependent manner \[[@CR83]\]. This modification is likely to regulate the complex-formation with the DNA checkpoint proteins, supported by the fact that cell exposure to irradiation induces Myc dissociation from USP28 \[[@CR82]\].

Phosphorylation of USP44 during Mitosis {#Sec15}
=======================================

USP44, a predominantly nuclear DUB and an important regulator of the spindle checkpoint, undergoes phosphorylation during mitosis \[[@CR84]\]. This step may activate USP44 specifically for the checkpoint arrest, regulated for instance by mitotic cyclin-dependent kinases or spindle checkpoint kinases \[[@CR85]\]. Moreover, USP44 is a documented target for Lys^48^- and Lys^63^-linked polyubiquitination, but the effect of these modifications is not yet understood \[[@CR84]\].

PTMs on DUBs Identified by Global Proteomics Studies {#Sec16}
====================================================

In addition to the biochemically-characterized examples of PTMs, several high-throughput studies aimed at mapping the phosphoproteome, ubiquitinome, and acetylome yielded information on additional post-translationally modified residues in DUBs (several such studies are summarized in Table [2](#Tab2){ref-type="table"}, \[[@CR65], [@CR86]--[@CR114]\]). Strikingly, large-scale phosphoproteomics studies have found 37 out of 55 USPs to be phosphorylated in vivo (reviewed in \[[@CR115]\]). Global phosphoproteome analyses targeted to a particular kinase might be of special value, placing a phosphorylated DUB within a biological context. For instance, Matsuoka et al. \[[@CR90]\] detected various DUBs as kinase substrates of ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3-related) in response to the DNA damage, which include USP1, UCHL3, USP19, USP24, USP28, and USP34, although the relevance of ATM/ATR-mediated phosphorylation of these enzymes is presently unclear \[[@CR90]\]. Furthermore, proteomic studies such as \[[@CR8]\] provide information on novel protein--protein interactions, including association with kinases, methyl transferases, and other proteins that might post-translationally modify DUBs.Table 2List of all known post-translational modifications (PTMs) of deubiquitinating enzymes (DUBs)Accession numberEntry nameProtein nameLengthPhosphorylation (residues)ReferencesAcetylation (residues)ReferencesUbiquitination/sumoylation (residues)ReferencesQ92560BAP1_HUMANUbiquitin carboxyl-terminal hydrolase BAP1729Ser327, Ser395, Thr487, Ser489, Ser582, Ser583, Ser592, Ser597\[[@CR65], [@CR86], [@CR87], [@CR90]\]Q9NQC7CYLD_HUMANUbiquitin carboxyl-terminal hydrolase CYLD956Ser399, Ser418\[[@CR34], [@CR35], [@CR88]\]P46736BRCC3_HUMANLys-63-specific deubiquitinase BRCC36316Q7RTX8HIN1L_HUMANPutative HIN1-like protein443Q5VVQ6OTU1_HUMANUbiquitin thioesterase OTU1 (OTU domain-containing protein 2) (DUBA-8)348Q7L8S5OTU6A_HUMANOTU domain-containing protein 6A (DUBA-2)288Q8N6M0OTU6B_HUMANOTU domain-containing protein 6B (DUBA-5)293Tyr272\[[@CR91]\]Met1\[[@CR86]\]Q8TE49OTU7A_HUMANOTU domain-containing protein 7A (Zinc finger protein Cezanne 2)926Q6GQQ9OTU7B_HUMANOTU domain-containing protein 7B (zinc finger protein cezanne) (zinc finger A20 domain-containing protein 1)843Ser100, Ser449, Ser464, Ser467\[[@CR65], [@CR86], [@CR87], [@CR92], [@CR93]\]Q96FW1OTUB1_HUMANUbiquitin thioesterase OTUB1 (otubain-1)271Ser16, Ser18, Tyr26\[[@CR50], [@CR92]\]Ala2, Lys188\[[@CR86], [@CR114]\]Q96DC9OTUB2_HUMANUbiquitin thioesterase OTUB2 (otubain-2)234Q5VV17OTUD1_HUMANOTU domain-containing protein 1 (DUBA-7)481Q5T2D3OTUD3_HUMANOTU domain-containing protein 3398Ser224\[[@CR92]\]Q01804OTUD4_HUMANOTU domain-containing protein 4 (HIV-1-induced protein HIN-1)1113Tyr438, Ser442, Ser556, Ser940, Ser1005, Ser1022, Ser1023\[[@CR86], [@CR88], [@CR89], [@CR92]--[@CR95]\]Met1\[[@CR86]\]Q96G74OTUD5_HUMANOTU domain-containing protein 5 (deubiquitinating enzyme A) (DUBA)571Ser64, Ser165, Tyr175, Ser177, Ser452, Thr507, Ser508\[[@CR86], [@CR92], [@CR93], [@CR96], [@CR97]\]Q504Q3PAN2_HUMANPAB-dependent poly(A)-specific ribonuclease subunit 2 (hPan2) (inactive ubiquitin carboxyl-terminal hydrolase 52)1202Ser791, Ser1189\[[@CR86], [@CR89], [@CR92]\]Q53GS9SNUT2_HUMANU4/U6.U5 tri-snRNP-associated protein 2 (U4/U6.U5 tri-snRNP-associated 65 kDa protein) (65 K) (inactive ubiquitin-specific peptidase 39)565Ser42, Ser46, Ser82\[[@CR88], [@CR92], [@CR98]\]Lys428\[[@CR114]\]P21580TNAP3_HUMANTumor necrosis factor alpha-induced protein 3 (TNF alpha-induced protein 3) (OTU domain-containing protein 7C) (putative DNA-binding protein A20) (zinc finger protein A20)790Ser459, Ser575, Ser381\[[@CR41], [@CR88], [@CR93]\]Q7RTZ2U17L1_HUMANPutative ubiquitin carboxyl-terminal hydrolase 17-like protein 1530Q6R6M4U17L2_HUMANUbiquitin carboxyl-terminal hydrolase 17-like protein 2 (deubiquitinating protein 3) (DUB-3)530A6NCW0U17L3_HUMANUbiquitin carboxyl-terminal hydrolase 17-like protein 3530A6NCW7U17L4_HUMANInactive ubiquitin carboxyl-terminal hydrolase 17-like protein 4530A8MUK1U17L5_HUMANUbiquitin carboxyl-terminal hydrolase 17-like protein 5530Q6QN14U17L6_HUMANUbiquitin carboxyl-terminal hydrolase 17-like protein 6398P0C7H9U17L7_HUMANInactive ubiquitin carboxyl-terminal hydrolase 17-like protein 7530P0C7I0U17L8_HUMANInactive ubiquitin carboxyl-terminal hydrolase 17-like protein 8530Q96FJ0STALP_HUMANAMSH-like protease (AMSH-LP) (STAM-binding protein-like 1)436Ser25, Ser242\[[@CR92]\]Q14694UBP10_HUMANUbiquitin carboxyl-terminal hydrolase 10798Thr42, Thr100, Thr208, Ser211, Ser220, Ser226, Ser337, Ser364, Ser365, Ser370, Ser547, Ser563, Ser576\[[@CR65], [@CR76], [@CR86], [@CR88], [@CR89], [@CR92], [@CR93], [@CR98]--[@CR102]\]P51784UBP11_HUMANUbiquitin carboxyl-terminal hydrolase 11963Ser948, Ser953\[[@CR92]\]Lys245\[[@CR114]\]O75317UBP12_HUMANUbiquitin carboxyl-terminal hydrolase 12370Q92995UBP13_HUMANUbiquitin carboxyl-terminal hydrolase 13 (isopeptidase T-3) (ISOT-3)863Ser114, Thr122\[[@CR92], [@CR93]\]P54578UBP14_HUMANUbiquitin carboxyl-terminal hydrolase 14494Tyr136, Ser143\[[@CR92], [@CR93], [@CR103]\]Lys291, Lys313, Lys449\[[@CR114]\]Q9Y4E8UBP15_HUMANUbiquitin carboxyl-terminal hydrolase 15981Ser229, Ser961, Ser965\[[@CR86], [@CR89], [@CR92], [@CR93]\]Ala2\[[@CR86]\]Q9Y5T5UBP16_HUMANUbiquitin carboxyl-terminal hydrolase 16823Ser415, Ser552, Thr554\[[@CR65], [@CR86], [@CR92], [@CR93]\]Q0WX57UBP17_HUMANUbiquitin carboxyl-terminal hydrolase 17530Q9UMW8UBP18_HUMANUbl carboxyl-terminal hydrolase 18 (ISG15-specific-processing protease)372O94966UBP19_HUMANUbiquitin carboxyl-terminal hydrolase 191318Ser244, Ser1242\[[@CR65], [@CR86], [@CR90]\]O94782UBP1_HUMANUbiquitin carboxyl-terminal hydrolase 1785Ser13, Ser42, Ser67, Ser313, Ser475\[[@CR86], [@CR90], [@CR92], [@CR96]\]Q9Y2K6UBP20_HUMANUbiquitin carboxyl-terminal hydrolase 20914Ser132, Ser134, Thr258, Ser263, Ser368, Ser373, Thr377, Ser406, Ser407, Ser413\[[@CR88], [@CR92], [@CR93], [@CR97]\]Q9UK80UBP21_HUMANUbiquitin carboxyl-terminal hydrolase 21565Q9UPT9UBP22_HUMANUbiquitin carboxyl-terminal hydrolase 22525Lys129\[[@CR114]\]Q9UPU5UBP24_HUMANUbiquitin carboxyl-terminal hydrolase 242620Ser1141, Ser1616, Ser1620, Ser1943, Tyr2024, Ser2047, Ser2077, Thr2559, Ser2561, Thr2565, Ser2604\[[@CR65], [@CR86]--[@CR90], [@CR92], [@CR93], [@CR97], [@CR102], [@CR104]--[@CR107]\]Q9UHP3UBP25_HUMANUbiquitin carboxyl-terminal hydrolase 251055Tyr740, Tyr916\[[@CR80], [@CR96]\]Lys99 (SUMO), Lys99 (Ub), Lys141 (SUMO)\[[@CR78], [@CR81]\]Q9BXU7UBP26_HUMANUbiquitin carboxyl-terminal hydrolase 26913A6NNY8UBP27_HUMANUbiquitin carboxyl-terminal hydrolase 27438Q96RU2UBP28_HUMANUbiquitin carboxyl-terminal hydrolase 281077Ser67, Ser714\[[@CR83], [@CR90]\]Q9HBJ7UBP29_HUMANUbiquitin carboxyl-terminal hydrolase 29922O75604UBP2_HUMANUbiquitin carboxyl-terminal hydrolase 2605Q70CQ3UBP30_HUMANUbiquitin carboxyl-terminal hydrolase 30517Q70CQ4UBP31_HUMANUbiquitin carboxyl-terminal hydrolase 311352Tyr428, Ser1052, Thr1056\[[@CR91], [@CR98]\]Q8NFA0UBP32_HUMANUbiquitin carboxyl-terminal hydrolase 321604Tyr1137, Ser1361, Ser1372, Ser1376,\[[@CR86], [@CR88], [@CR92], [@CR93]\]Q8TEY7UBP33_HUMANUbiquitin carboxyl-terminal hydrolase 33942Ser439\[[@CR92]\]Q70CQ2UBP34_HUMANUbiquitin carboxyl-terminal hydrolase 343546Ser352, Ser355, Ser649, Ser658, Ser1503, Ser2488, Ser3358, Ser3359, Thr3381, Ser3406\[[@CR90], [@CR92], [@CR93], [@CR104]\]Q9P2H5UBP35_HUMANUbiquitin carboxyl-terminal hydrolase 351017Ser612\[[@CR92]\]Q9P275UBP36_HUMANUbiquitin carboxyl-terminal hydrolase 361121Ser464, Ser494, Ser513, Ser515, Ser546, Ser582, Ser613, Ser614, Thr653, Ser667, Thr680, Ser682, Ser713, Ser742, Tyr874, Ser952, Ser1048\[[@CR86], [@CR88], [@CR92], [@CR93], [@CR96], [@CR97], [@CR106], [@CR108]\]Q86T82UBP37_HUMANUbiquitin carboxyl-terminal hydrolase 37979Ser650, Ser652\[[@CR86], [@CR88], [@CR92], [@CR104]\]Q8NB14UBP38_HUMANUbiquitin carboxyl-terminal hydrolase 381042Q9Y6I4UBP3_HUMANUbiquitin carboxyl-terminal hydrolase 3520Thr141\[[@CR104]\]Met1\[[@CR86]\]Q9NVE5UBP40_HUMANUbiquitin carboxyl-terminal hydrolase 401235Q3LFD5UBP41_HUMANPutative ubiquitin carboxyl-terminal hydrolase 41358Q9H9J4UBP42_HUMANUbiquitin carboxyl-terminal hydrolase 421325Ser754, Ser856, Tyr953, Ser1220, Ser1223, Ser1227\[[@CR65], [@CR86], [@CR88], [@CR92], [@CR93], [@CR97]\]Q70EL4UBP43_HUMANUbiquitin carboxyl-terminal hydrolase 431123Tyr835, Ser1041\[[@CR92], [@CR95]\]Q9H0E7UBP44_HUMANUbiquitin carboxyl-terminal hydrolase 44712Q70EL2UBP45_HUMANUbiquitin carboxyl-terminal hydrolase 45814P62068UBP46_HUMANUbiquitin carboxyl-terminal hydrolase 46366Q96K76UBP47_HUMANUbiquitin carboxyl-terminal hydrolase 471375Ser832, Tyr836, Ser910, Ser1353\[[@CR65], [@CR86], [@CR89], [@CR92], [@CR93], [@CR97], [@CR107]\]Lys122\[[@CR114]\]Q86UV5UBP48_HUMANUbiquitin carboxyl-terminal hydrolase 481035Ser886, Ser887, Ser888, Thr890\[[@CR86], [@CR88]\]Lys856\[[@CR114]\]Q70CQ1UBP49_HUMANUbiquitin carboxyl-terminal hydrolase 49688Q13107UBP4_HUMANUbiquitin carboxyl-terminal hydrolase 4963Q70EL3UBP50_HUMANInactive ubiquitin carboxyl-terminal hydrolase 50339Q70EK8UBP53_HUMANInactive ubiquitin carboxyl-terminal hydrolase 531073Q70EL1UBP54_HUMANInactive ubiquitin carboxyl-terminal hydrolase 541684P45974UBP5_HUMANUbiquitin carboxyl-terminal hydrolase 5 (isopeptidase T)858Thr623, Ser783\[[@CR89], [@CR93], [@CR96]\]Ala2, Lys184\[[@CR86], [@CR114]\]P35125UBP6_HUMANUbiquitin carboxyl-terminal hydrolase 61406Q93009UBP7_HUMANUbiquitin carboxyl-terminal hydrolase 71102Ser18, Ser49, Thr54, Ser963\[[@CR65], [@CR86], [@CR92], [@CR93]\]Lys595, Lys869, Lys1084, Lys1096\[[@CR114]\]Lys869 (Ub)\[[@CR66]\]P40818UBP8_HUMANUbiquitin carboxyl-terminal hydrolase 8 (ubiquitin isopeptidase Y) (UBPy)1118Ser434, Ser452, Ser680, Ser718, Ser719, Thr907\[[@CR72], [@CR74], [@CR75], [@CR86], [@CR92], [@CR93], [@CR96]\]P09936UCHL1_HUMANUbiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1)223Met1\[[@CR86]\]Lys4 (Ub), Lys65 (Ub), Lys71 (Ub), Lys157 (Ub)\[[@CR57]\]P15374UCHL3_HUMANUbiquitin carboxyl-terminal hydrolase isozyme L3 (UCH-L3)230Ser75, Ser130\[[@CR90], [@CR92], [@CR93]\]Q9Y5K5UCHL5_HUMANUbiquitin carboxyl-terminal hydrolase isozyme L5 (UCH-L5) (ubiquitin *C*-terminal hydrolase UCH37)329Lys158\[[@CR114]\]Q92738US6NL_HUMANUSP6 *N*-terminal-like protein (related to the *N*-terminus of tre)828Ser391, Ser396, Tyr582, Ser585, Ser617, Ser680, Tyr710, Ser716, Tyr729\[[@CR86], [@CR88], [@CR90], [@CR92], [@CR93], [@CR105]\]Q93008USP9X_HUMANProbable ubiquitin carboxyl-terminal hydrolase FAF-X (fat facets protein-related, X-linked) (fat facets in mammals) (hFAM)2547Thr583, Ser1593, Ser2436, Tyr2533, Ser2540\[[@CR86], [@CR88], [@CR89], [@CR92]--[@CR94], [@CR97], [@CR100]\]O00507USP9Y_HUMANProbable ubiquitin carboxyl-terminal hydrolase FAF-Y (fat facets protein-related, Y-linked) (ubiquitin-specific protease 9, Y chromosome)2555Q5W0Q7USPL1_HUMANUbiquitin-specific peptidase-like protein 11092Q96JH7VCIP1_HUMANDeubiquitinating protein VCIP135 (valosin-containing protein p97/p47 complex-interacting protein p135)1222Ser747, Ser757, Thr761, Thr763, Tyr767, Thr770, Ser994, Ser998, Ser1198\[[@CR65], [@CR86], [@CR92], [@CR93]\]Lys408\[[@CR114]\]Lys870 (Ub)\[[@CR110]\]Q8TAF3WDR48_HUMANWD repeat-containing protein 48 (WD repeat endosomal protein) (USP1-associated factor 1) (p80)677Lys121, Lys214, Lys578\[[@CR114]\]Q9UGI0ZRAN1_HUMANUbiquitin thioesterase ZRANB1 (zinc finger Ran-binding domain-containing protein 1) (hTrabid)708Lys260\[[@CR114]\]P54252ATX3_HUMANAtaxin-3 (Machado-Joseph disease protein 1) (spinocerebellar ataxia type 3 protein)364Ser340, Ser352\[[@CR46]\]Q8N594MPND_HUMANMPN domain-containing protein471Ser178, Ser181\[[@CR88]\]Q5VVJ2MYSM1_HUMANHistone H2A deubiquitinase MYSM1 (2A-DUB)828Ser218, Ser234, Thr236, Ser267\[[@CR90], [@CR92], [@CR93]\]O00487PSDE_HUMAN26S proteasome non-ATPase regulatory subunit 14310Tyr32, Ser150, Ser224\[[@CR94], [@CR100], [@CR109]\]The large portion of the data consists of PTMs detected in the global proteomics analyses, but it also includes modifications detected in targeted studies summarized in Table [1](#Tab1){ref-type="table"} (source: <http://www.uniprot.org/> and listed references)*Ub* ubiquitin, *SUMO* small ubiquitin-related modifier

All this indicates that the number of the PTMs affecting DUBs must be extensive, providing a great scope for future studies exploring roles of these already discovered modifications. Location of the modifiable residues within various DUB domains might give an initial clue on the mechanistic effect of PTMs on DUB function. For instance, different outcomes are to be expected for modifications occurring within the ubiquitin-binding domain, components of the catalytic site, or protein--protein interaction domains.

Multi-PTM Crosstalk {#Sec17}
===================

Although there are multiple examples of post-translationally modified DUBs, the biochemical data is too scarce to draw any general conclusions, especially in relation to PTM-mediated regulation of the catalytic activity of DUBs. Future studies are likely to reveal trans-regulatory mechanisms of PTMs in the control of DUB catalytic activity and function. Such complex crosstalks between pathways have been recognized for many proteins, perhaps best described for kinases and histones. For instance, in some cases priming phosphorylation events are necessary to enable subsequent phosphorylation, sumoylation, or ubiquitination, while methylation or ubiquitination of certain residues in histones might be a prerequisite for their acetylation (reviewed in \[[@CR116]\]). So far, no example of a similar mechanism has been discovered for DUBs, but they are anticipated. In particular, an occurrence of a phosphodegron, or a priming phosphorylation event necessary for recognition by an E3 ubiquitin ligase, leading to ubiquitination and proteasomal degradation, should be carefully examined for DUBs down-regulated by phosphorylation events. For instance, phosphorylation of USP25 \[[@CR80]\] might trigger subsequent Lys^48^-polyubiquitination resulting in proteasomal degradation. On the other hand, phosphorylation-driven negative regulation of ubiquitination might also be common. For example, it would be interesting to investigate this mechanism for USP8, since phosphorylation of Thr^907^ leads to accumulation of this protein \[[@CR74], [@CR75]\]. Another attractive aspect of post-translational events is a direct competition for a modifiable residue, such as for USP25, where Lys^99^ has been shown to be both ubiquitinated and sumoylated, with a potentially opposite functional outcome \[[@CR78], [@CR81]\].

Auto-Regulatory Mechanisms Keep DUBs in Check {#Sec18}
=============================================

Internal adaptive mechanisms controlling kinase enzymatic activity and therefore cell homeostasis have been known for a long time (reviewed in \[[@CR117], [@CR118]\]), but they have also been described for E3 ubiquitin ligases (e.g., Smurf2 \[[@CR119]\]) and acetyltransferases (e.g., Rtt109 \[[@CR120]\]). Since attachment of ubiquitin or ubiquitin-like molecules to protein substrates has been recognized as a multi-purpose regulatory modification, self-deubiquitination represents an attractive means of auto-regulation, whether it concerns control over lifespan, localization, or catalytic activity of DUBs. Indeed, this principle has been proposed for UCH-L1 \[[@CR57]\], USP6 \[[@CR59]\], and USP25 \[[@CR78]\]. Monoubiquitination is particularly interesting since it impairs deubiquitinating properties of UCH-L1, while USP25 catalytic activity is most likely induced by this PTM \[[@CR57], [@CR78]\]. These studies indicate that auto-deubiquitination might contribute to both, inhibition and activation of the DUB function.

Further knowledge on how DUB function is regulated by PTMs may provide novel insights into their biology. Moreover, since many DUBs are implicated in cancer, inflammation, microbial disease, and neurodegeneration, novel insights into PTM-mediated regulation of DUBs might provide opportunities for combining inhibitors of DUBs and enzymes responsible for regulatory PTMs (e.g., kinase or phosphatase inhibitors) as more efficient entry points for pharmacological intervention strategies.

B.M.K. is supported by the NIHR Biomedical Research Centre, Oxford, UK, and an Action Medical Research Grant (Charity No. 208701 and SC039284). M.J.E. is supported by the USDA NIFA grant 2009-34609-20222. Approved for publication as Journal Article No. J-12003 of the Mississippi Agricultural and Forestry Experiment Station, Mississippi State University.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
